Maven Brands (TLA) 주식 개요Together with its subsidiary, engages in the production, toll-processing, and packaging of medical cannabis in Canada. 자세히 보기TLA 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6강점공정 가치 추정치보다 낮은 55.9% 에서 거래위험 분석의미 있는 시가총액이 없습니다(€481K)수익이 USD$1m 미만입니다(CA$0)마이너스 주주 지분주식은 유동성이 매우 낮습니다+ 위험 1건 추가모든 위험 점검 보기TLA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.0005해당 없음내재 할인율Est. Revenue$PastFuture-16m2m2016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesMaven Brands Inc. 경쟁사TFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.2mbioXXmedSymbol: XTRA:T5O0Market cap: €329.8kEpigenomicsSymbol: DB:ECXMarket cap: €815.6k가격 이력 및 성과Maven Brands 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.000552주 최고가CA$0.02752주 최저가CA$0.0005베타2.581개월 변동0%3개월 변동0%1년 변동0%3년 변동-99.82%5년 변동-99.98%IPO 이후 변동-99.93%최근 뉴스 및 업데이트Buying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.더 많은 업데이트 보기Recent updatesBuying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Jun 17Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 69%. The fair value is estimated to be €0.008, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • May 29Now 34% undervaluedOver the last 90 days, the stock is up 400%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Apr 26Now 21% undervaluedOver the last 90 days, the stock is up 2,500%. The fair value is estimated to be €0.016, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Apr 05Now 24% undervaluedOver the last 90 days, the stock is up 1,000%. The fair value is estimated to be €0.0073, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.Buying Opportunity • Mar 09Now 35% undervalued after recent price dropOver the last 90 days, the stock is down 50%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 170% over the last 3 years. Earnings per share has grown by 80%.공시 • Nov 22Maven Brands Inc., Annual General Meeting, Jan 31, 2023Maven Brands Inc., Annual General Meeting, Jan 31, 2023.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Feb 19Founder & Director recently sold €153k worth of stockOn the 17th of February, Darcy Bomford sold around 339k shares on-market at roughly €0.45 per share. This was the largest sale by an insider in the last 3 months. This was Darcy's only on-market trade for the last 12 months.주주 수익률TLADE PharmaceuticalsDE 시장7D0%4.8%-1.5%1Y0%34.7%1.9%전체 주주 수익률 보기수익률 대 산업: TLA은 지난 1년 동안 34.7%의 수익을 기록한 German Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: TLA은 지난 1년 동안 1.9%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is TLA's price volatile compared to industry and market?TLA volatilityTLA Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.8%Market Average Movement5.8%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.8%안정적인 주가: TLA의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine TLA의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2013n/aDarcy Bomfordmavenbrands.ca더 보기Maven Brands Inc. 기초 지표 요약Maven Brands의 순이익과 매출은 시가총액과 어떻게 비교됩니까?TLA 기초 통계시가총액€480.67k순이익 (TTM)-€518.16k매출 (TTM)n/a0.0x주가매출비율(P/S)-0.9x주가수익비율(P/E)TLA는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표TLA 손익계산서 (TTM)매출CA$0매출원가CA$0총이익CA$0기타 비용CA$757.63k순이익-CA$757.63k최근 보고된 실적Dec 31, 2022다음 실적 발표일해당 없음주당순이익(EPS)-0.022총이익률0.00%순이익률0.00%부채/자본 비율-341.6%TLA의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/07 05:24종가2023/10/10 00:00수익2022/12/31연간 수익2022/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Maven Brands Inc.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Buying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Oct 05Now 56% undervalued after recent price dropOver the last 90 days, the stock is down 92%. The fair value is estimated to be €0.0011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Sep 19Now 45% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-CA$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (€731.1k market cap, or US$779.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
Buying Opportunity • Sep 04Now 45% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Aug 02Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 79%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jul 14Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 81%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Jun 17Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 69%. The fair value is estimated to be €0.008, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • May 29Now 34% undervaluedOver the last 90 days, the stock is up 400%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Apr 26Now 21% undervaluedOver the last 90 days, the stock is up 2,500%. The fair value is estimated to be €0.016, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Apr 05Now 24% undervaluedOver the last 90 days, the stock is up 1,000%. The fair value is estimated to be €0.0073, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 171% over the last 3 years. Earnings per share has grown by 80%.
Buying Opportunity • Mar 09Now 35% undervalued after recent price dropOver the last 90 days, the stock is down 50%. The fair value is estimated to be €0.0038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 170% over the last 3 years. Earnings per share has grown by 80%.
공시 • Nov 22Maven Brands Inc., Annual General Meeting, Jan 31, 2023Maven Brands Inc., Annual General Meeting, Jan 31, 2023.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Mike Harcourt was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Feb 19Founder & Director recently sold €153k worth of stockOn the 17th of February, Darcy Bomford sold around 339k shares on-market at roughly €0.45 per share. This was the largest sale by an insider in the last 3 months. This was Darcy's only on-market trade for the last 12 months.
